A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

(2017) A. Stathis et al.   INVESTIGATIONAL NEW DRUGS

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies

(2017) Alberto Ocana et al.   Oncotarget

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors

(2016) Varun Goel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sonidegib for the treatment of advanced basal cell carcinoma

(2016) Egle Ramelyte et al.   EXPERT OPINION ON PHARMACOTHERAPY

Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer

(2016) Katsuhiko Nakatsukasa et al.   Breast Cancer

Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma

(2016) Hung Doan et al.   OncoTargets and Therapy

Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma

(2016) Hyung Wook Chun et al.   Oncology Letters

The hedgehog pathway in triple-negative breast cancer

(2016) Joyce G. Habib et al.   Cancer Medicine

Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness

(2016) Sirunya Silapunt et al.   Therapeutic Advances in Medical Oncology

Taxane anticancer agents: a patent perspective

(2015) Iwao Ojima et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

The role of taxanes in triple-negative breast cancer: literature review

(2015) Giorgio Mustacchi et al.   Drug Design Development and Therapy

Subtyping of triple-negative breast cancer: Implications for therapy

(2014) Vandana G. Abramson et al.   CANCER

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

(2014) J. Rodon et al.   CLINICAL CANCER RESEARCH

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer

(2012) A. D. Steg et al.   MOLECULAR CANCER THERAPEUTICS

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of Mammary Tumors by Conditional Expression of GLI1

(2009) M. Fiaschi et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER